BioPharma Dive - Latest News

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema. 

Jun 16, 2025 - 15:00
 0
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema. 

Read More

Tags:

Previous Article

Which Sports Cars Would Be Better With A Safari Variant?

Next Article

Second Duchenne patient dies after receiving Sarepta gene therapy

Related Posts

FDA panel backs Darzalex for early stage multiple myeloma

FDA panel backs Darzalex for early stage multiple myeloma

May 21, 2025  0

Vera drug scores in closely watched study in rare kidney disease

Vera drug scores in closely watched study in rare kidne...

Jun 2, 2025  0

Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal

Cullinan doubles down on bispecifics for autoimmune dis...

Jun 5, 2025  0